RainDance Closes $16.5M Series E Financing Round Extension | GenomeWeb

NEW YORK (GenomeWeb News) – RainDance Technologies today said that it has closed a $16.5 million Series E financing round extension.

New investors GE Healthcare and Northgate Capital participated in the round as did existing investors. The financing, Billerica, Mass.-based RainDance said, will be used to accelerate its commercial expansion and assay development work.

RainDance also is developing a liquid biopsy method that uses "readily accessible fluids" and is minimally invasive and inexpensive, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.